The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast), taken as oral tablets, as a treatment for adults with progressive pulmonary fibrosis (PPF), in which lung scarring worsens over time. “Progressive pulmonary fibrosis is a life-threatening condition with a high unmet medical need. The U.S. approval…
Amid a sea of data, the PF community is critical in the search for a cure
Treatment with GRI-0621, an experimental oral therapy from GRI Bio, boosts lung function in adults with idiopathic pulmonary fibrosis (IPF), according to top-line data from a Phase 2a clinical trial. The study (NCT06331624) met its primary goal, demonstrating no safety or tolerability concerns after 12 weeks of…
What is your earliest memory of the holidays? Whether you celebrate Hanukkah, Christmas, Kwanzaa, or another occasion, do you have memories of these holidays from your youth? How do they differ from more recent years? My earliest memories of Christmas are associated with gifts, such as acoustic and electric guitars,…
There are moments in life when love challenges us to rise in unexpected ways, testing our resilience and adaptability while revealing the quiet strengths we didn’t know we had. I am currently experiencing one of those moments. As I prepare for a lung transplant and navigate the unpredictable journey of…
Hello! My name is Kylene Henderson, and I’m excited to be writing a new column for Pulmonary Fibrosis News called “Life Beyond Limits.” In it, I hope to share some of the challenges our family has faced and the lessons we’ve learned since my husband Donnie’s pulmonary fibrosis diagnosis…
Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic pulmonary fibrosis (IPF). “We are now advancing this pivotal program with urgency to bring forward a…
I was sound asleep at 3 a.m. on Nov. 25 when I heard my mother call my name. It didn’t sound like she was in distress; it was more like she needed help reaching something on a shelf in the next room. After I awoke, I had some trouble processing…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Birchbiomed’s FS2 (kynurenic acid) for the treatment of idiopathic pulmonary fibrosis (IPF). Orphan drug status is intended to incentivize the development of therapies for rare diseases — defined as those affecting fewer than 200,000 people in the…
I conduct research for each of my columns primarily because I want a broader perspective on a topic. Recently, I discussed what should be packed in a “go bag” for a transplant patient receiving the call that donor lungs are available. When I typed “transplant go bag” into a Google…
